Trials / Sponsors / Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Industry · 4 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Completed | A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis | Phase 3 | 2019-06-13 |
| Completed | To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Pa Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis | Phase 2 | 2018-03-15 |
| Completed | To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Ch Healthy Chinese Volunteers | Phase 1 | 2017-10-17 |
| Completed | To Evaluate the Safety, Tolerability, and Pharmacokinetics Profile in Healthy Chinese Volunteers of TG-2349 Healthy Chinese Volunteers | Phase 1 | 2017-04-27 |